alexa Oral Vaccine Platform Elicits Neutralizing Antibody Responses To Influenza
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Sean Tucker
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
Introduction: Influenza vaccine compliance is difficult to measure, but according to the CDC, the National Immunization Survey and National Internet Flu Survey has determined that only 45% of persons were immunized this season. An oral tablet vaccine may increase immunization uptake because several distribution bottlenecks can be avoided, potentially even allowing for vaccine delivery through the regular mail. Objective: To test oral immunization (using a non-replicating adenoviral based vector expressing influenza HA and dsRNA) for the ability to elicit immune responses to influenza in humans. Methods: Two phase I clinical trials testing the vector were completed where humoral immune responses were measured by standard influenza assays. Additionally, flow cytometry was used for detailing the mucosal and cellular immune response to the influenza antigen HA. Results: A dose dependent immune response to influenza HA was shown; both T cell and antibody responses were observed, with up to 100% of subjects having an antibody and cellular response specific to HA and up to 67% seroconversion as measured by HAI assay. Mucosal immune responses were observed by flow cytometry and by measuring specific IgA in nasal and fecal samples. Conclusions: Oral immunization can induce substantial HAI seroconversion and induce a mucosal immune response in humans, suggesting that this approach may become a viable and efficacious influenza vaccine.
Sean Tucker completed his Doctoral degree in Immunology at the University of Washington. He is the Chief Scientific Officer and Vice President for Research at Vaxart, Inc., a company focused on mucosal vaccine delivery. He has published several papers in immunology and served as a grant reviewer for several vaccine related study sections at the NIH.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version